Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

The median survival for patients with locally advanced pancreatic cancer treated with gemcitabine and radiation is approximately 1 year. To develop improved treatment, we have combined a Chk1/2-targeted agent, AZD7762, currently in phase I clinical trials, with gemcitabine and ionizing radiation in preclinical pancreatic tumor models. We found that in vitro AZD7762 alone or in combination with gemcitabine significantly sensitized MiaPaCa-2 cells to radiation. AZD7762 inhibited Chk1 autophosphorylation (S296 Chk1), stabilized Cdc25A, and increased ATR/ATM-mediated Chk1 phosphorylation (S345 Chk1). Radiosensitization by AZD7762 was associated with abrogation of the G(2) checkpoint as well as with inhibition of Rad51 focus formation, inhibition of homologous recombination repair, and persistent gamma-H2AX expression. AZD7762 was also a radiation sensitizer in multiple tumor xenograft models. In both MiaPaCa-2- and patient-derived xenografts, AZD7762 significantly prolonged the median time required for tumor volume doubling in response to gemcitabine and radiation. Together, our findings suggest that G(2) checkpoint abrogation and homologous recombination repair inhibition both contribute to sensitization by Chk1 inhibition. Furthermore, they support the clinical use of AZD7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.

[1]  N. Mailand,et al.  Rapid destruction of human Cdc25A in response to DNA damage. , 2000, Science.

[2]  Z. Darżynkiewicz,et al.  Detection of Histone H2AX Phosphorylation on Ser‐139 as an Indicator of DNA Damage (DNA Double‐Strand Breaks) , 2004, Current protocols in cytometry.

[3]  H. Stürzbecher,et al.  DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma , 2000, Oncogene.

[4]  M. Gonen,et al.  Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Abraham,et al.  Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. , 2005, Molecular cell.

[6]  R. Pierce,et al.  Abstract #2490: Targeting the replication checkpoint with a potent and selective CHK1 inhibitor , 2009 .

[7]  J. Bourhis,et al.  Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints , 2009, Cell cycle.

[8]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[9]  Huichen Wang,et al.  Caffeine Could Not Efficiently Sensitize Homologous Recombination Repair-Deficient Cells to Ionizing Radiation-Induced Killing , 2003, Radiation research.

[10]  Anja Gebauer,et al.  Single-Strand Annealing, Conservative Homologous Recombination, Nonhomologous DNA End Joining, and the Cell Cycle-Dependent Repair of DNA Double-Strand Breaks Induced by Sparsely or Densely Ionizing Radiation , 2009, Radiation research.

[11]  P. Lyne,et al.  Inhibitors of checkpoint kinases: from discovery to the clinic. , 2007, Current opinion in drug discovery & development.

[12]  M. Strawderman,et al.  Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Stephen Green,et al.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies , 2008, Molecular Cancer Therapeutics.

[14]  C. Rosty,et al.  Molecular pathogenesis of pancreatic cancer. , 2002, Hematology/oncology clinics of North America.

[15]  T. Lawrence,et al.  The Relationship of Premature Mitosis to Cytotoxicity in Response to Checkpoint Abrogation and Antimetabolite Treatment , 2006, Cell cycle.

[16]  T. Lawrence,et al.  Improving Gemcitabine-mediated Radiosensitization Using Molecularly Targeted Therapy: a Review Gemcitabine Biochemistry and Radiosensitization Cellular Effects of Radiation and Gemcitabine Radiation Oncology, And , 2022 .

[17]  M. Lindstrom,et al.  Global comparison of radiation and chemotherapy dose-response curves with a test for interaction. , 1993, Radiation research.

[18]  Jiri Bartek,et al.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair , 2005, Nature Cell Biology.

[19]  C. Britten,et al.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer , 2008, British Journal of Cancer.

[20]  Xiang Wang,et al.  The Radioresistance to Killing of A1–5 Cells Derives from Activation of the Chk1 Pathway* , 2001, The Journal of Biological Chemistry.

[21]  S. Vispé,et al.  Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation. , 1998, Nucleic acids research.

[22]  H. Piwnica-Worms,et al.  Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. , 2000, Cancer research.

[23]  H. Groen,et al.  Selective targeting of homologous DNA recombination repair by gemcitabine. , 2003, International journal of radiation oncology, biology, physics.

[24]  S. Ashwell,et al.  DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy , 2008, Clinical Cancer Research.

[25]  T. Lawrence,et al.  Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. , 2005, Cancer research.

[26]  Junjie Chen,et al.  Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival , 2005, Molecular Pharmacology.

[27]  B. Anachkova,et al.  The Complexity of Double-Strand Break Ends is a Factor in the Repair Pathway Choice , 2009, Radiation research.

[28]  T. Lawrence,et al.  Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. , 1996, International journal of radiation oncology, biology, physics.

[29]  Sonnet J. H. Arlander,et al.  Hsp90 Inhibition Depletes Chk1 and Sensitizes Tumor Cells to Replication Stress* , 2003, Journal of Biological Chemistry.

[30]  Haiyong Han,et al.  Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. , 2002, Cancer research.

[31]  T. Lawrence,et al.  Ouabain sensitizes tumor cells but not normal cells to radiation. , 1987, International journal of radiation oncology, biology, physics.

[32]  T. Lawrence,et al.  The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer , 2008, Clinical Cancer Research.

[33]  Jonathan Maybaum,et al.  Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells , 2009, Molecular Cancer Therapeutics.

[34]  M. Broggini,et al.  Chk1, but not Chk2 , is Involved in the Cellular Response to DNA Damaging Agents: Differential Activity in Cells Expressing, or not, p53 , 2004, Cell cycle.

[35]  L. Karnitz,et al.  Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In Vivo , 2007, Cell cycle.

[36]  A. Benson,et al.  A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201 , 2008 .

[37]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[38]  T. Lawrence,et al.  Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells. , 2008, Translational oncology.

[39]  B. Fertil,et al.  Mean Inactivation Dose: A Useful Concept for Intercomparison of Human Cell Survival Curves , 1984, Radiation research.

[40]  P. O'Connor,et al.  Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 , 2008, Molecular Cancer Therapeutics.

[41]  L. Thompson,et al.  XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. , 1999, Genes & development.

[42]  E. Sausville,et al.  UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. , 1996, Journal of the National Cancer Institute.

[43]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[44]  Hui Zhao,et al.  Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  M. Broggini,et al.  Checkpoint Kinase 1 Down-Regulation by an Inducible Small Interfering RNA Expression System Sensitized In vivo Tumors to Treatment with 5-Fluorouracil , 2008, Clinical Cancer Research.

[46]  J. Bartek,et al.  Inhibition of Chk1 by CEP-3891 Accelerates Mitotic Nuclear Fragmentation in Response to Ionizing Radiation , 2004, Cancer Research.

[47]  R. Schimke,et al.  Thermal denaturation of DNA for immunochemical staining of incorporated bromodeoxyuridine (BrdUrd): critical factors that affect the amount of fluorescence and the shape of BrdUrd/DNA histogram. , 1989, Cytometry.

[48]  E. Sausville,et al.  Review of UCN‐01 Development: A Lesson in the Importance of Clinical Pharmacology , 2005, Journal of clinical pharmacology.